


SUITABILITY OF SACUBITRIL VALSARTAN PRESCRIPTIONS IN A HEALTH MANAGEMENT AREA

Valencia Soto CM¹, Pastor Hurtado J¹, Toscano Guzmán MD², Guijarro Herrera S³, Villacañas Palomares MV⁴, Cortés de Miguel S¹, Ruiz González JM¹, Román Márquez E¹.

¹AGS NORTE ALMERÍA-HOSPITAL LA INMACULADA (HUÉRCAL OVERA, ALMERÍA), ²DISTRITO PONIENTE (EL EJIDO, ALMERÍA), ³HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES (GRANADA), ⁴HOSPITAL GUTIERREZ ORTEGA (VALDEPEÑAS, CIUDAD REAL)

Background


In Spain, therapeutic positioning report (TPR) for sacubitril valsartan indicates its use



In adult patients for symptomatic chronic heart failure and:

- ✓ Reduced ejection fraction (LVEF < 35%)
- ✓ Elevated B-type natriuretic peptide (BNP) serum levels
- ✓ Well previously treated with standard of care therapy

Objective



To evaluate the suitability of sacubitril valsartan prescriptions to the recommendations in a health management area.

Materials and methods

Retrospective descriptive study including patients treated with sacubitril valsartan from September 2016 until July 2017.

VARIABLES

Sex, age, treatment with ACE inhibitors, beta-blockers, mineralocorticoid antagonists and/or diuretics, dosage regimen, contraindications or intolerance to standard therapy, LVEF, dose escalation, dose reduction, discontinuation and cause of discontinuation.

To evaluate the suitability of the prescriptions we analysed: intolerance/contraindications to standard therapy, therapy before change, dosage regimen, dose titration and LVEF ≤ 35%.

✓ Audit data were sent to their prescribers to review.


✓ To data compilation we used the Microstrategy® prescription database and medical records.

Results

53 patients. Median age 66.6 years. 83% (n=44) men.

ACE inhibitors/ARBs (%)


■ YES ■ NO



11,3% (n=6) optimal dose

Beta-blockers (%)


■ YES ■ NO



9,4% (n=5) optimal dose

Mineralocorticoid antagonists


■ YES ■ NO



0,5% (n=3) optimal dose

LVEF

■ > 35% ■ ≤ 35%



✓ No intolerance or contraindication to standard therapy

✓ Correct dose titration / appropriate periodic exam: 16 patients (30%).

✓ 1 dose reduction for hypotension and 10 discontinuations: 4 lack of indication, 2 hypotension, 1 exitus, 1 cardiac transplantation and 1 economic conditions.

Conclusions

✓ The results show an inadequate use of sacubitril valsartan according to TPR indications in most cases.

✓ With this analysis we intend to improve sacubitril valsartan use in our reference area.

✓ Audit are an effective method to improve rational use of medicines.